What is Foundayo?
Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist tablet approved by the U.S. FDA for chronic weight management in eligible adults when used with reduced-calorie diet and increased physical activity.
Why it matters
Foundayo is getting attention because it is an oral GLP-1 option in a market known mainly for injections.
What it is for
Public sources describe it for chronic weight management in adults who meet specific eligibility criteria.
Independent page
This site summarizes public references and does not give personal medical advice.
Clear overview
Foundayo is not an injection. Public drug references describe it as a tablet form of orforglipron, a small-molecule GLP-1 receptor agonist. GLP-1 medicines are associated with appetite and weight-management pathways.
The FDA approval announcement states that Foundayo is used together with reduced-calorie diet and increased physical activity to reduce excess body weight and help maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related comorbidity.
Why people are searching for it
- It is an oral GLP-1 option, unlike many widely known injectable weight-loss medicines.
- The FDA described the approval as notable under its National Priority Voucher program.
- People are comparing it with other GLP-1 medicines and searching for side effects, availability, cost, and dosing information.
Important guides
Foundayo vs Ozempic: What is the difference?
A simple comparison of oral Foundayo and injectable GLP-1 medicines.
Read article →Foundayo side effects and warnings
A source-based overview of common side effects and safety topics.
Read article →When was Foundayo approved?
The FDA approval timeline and why the announcement matters.
Read article →Foundayo dosage: what sources say
Listed tablet strengths and dosing context from public references.
Read article →Key facts from public sources
- FDA approval date: April 1, 2026.
- The FDA granted approval to Eli Lilly and Company.
- Drugs.com lists tablet strengths including 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg.
- Public references list gastrointestinal side effects and other warnings that should be checked in official labeling.
Frequently asked questions
What is Foundayo?
Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist described by public sources for chronic weight management in eligible adults.
Is Foundayo a pill or injection?
Public references describe Foundayo as a once-daily oral tablet.
Is this website medical advice?
No. This website is a neutral informational guide and does not provide personal medical advice.
Where should details be verified?
Details should be verified through official labeling, the FDA, trusted drug references, the manufacturer, and a licensed clinician.